cropped-gtc_logo_grey_circle_2022

Study shows that RNA Plus DNA profiling significantly enhanced Drug Matching

RNA Plus DNA profiling significantly enhanced Drug Matching

Recent study published in Nature Medicine (Rodon et al, Nature Medicine volume 25, pages 751–758, 2019) showed that molecular profiling using both DNA and RNA significantly enhanced therapy recommendation and patient outcome.  A third of the studied patients got drug therapy recommendation when both RNA and DNA testing was performed.

Genomic testing cooperative (GTC) offers combined RNA and DNA profiling without significant increase in cost.  Order GTC Solid Tumor PLUS or GTC Hematology PLUS for proper RNA and DNA profiling.

In addition to DNA profiling (SNV, indels, TMB, and MSI), thorough molecular profiling requires RNA profiling.  GTC RNA testing provides important information on fusion/translocation (ALK, ROS1, RET, NTRK, BCR-ABL1, EWRS1, ..), expression levels (MYC, Ki67, PDL1…) and exon skipping (MET exon 14, NTRK…).

•    Reference:
– Rodon J, et al “Genomic and transcriptomic profiling expands precision cancer medicine: The WINTHER trial” Nature Med 2019; 25:751-758.

YOU MAY ALSO ENJOY THESE ARTICLES:

ASCO 25 Posters

GTC presented abstracts at ASCO 2025 GTC’s posters from the 2025 Convention of the American Society of Clinical Oncology are now available for download. Please reach out with any questions.

Read More »

GTC featured in OC Business Journal

GTC Expands Cancer Tests to Europe via Partnership By Yuika Yoshida April 7, 2025  Genomic Testing Cooperative (GTC) is expanding into the European market by partnering with German laboratory Labor Dr. Wisplinghoff. 

Read More »

Subscribe to our Newsletter

Get all the critical news and events sent straight to your inbox

Share this post with your friends

Leave a Reply